GlassScriptPhysician profile
Neysha J Sanchez Rivera
NPI 1629481569
$3,935.73
in general payments reported to CMS, 2019-2025
28 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $179 · 2021: $67.66 · 2022: $834 · 2023: $1,074 · 2024: $924 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,651 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,650.71 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $524.58 | 2020-2025 | Krystexxa, Tavneos, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $490.25 | 2019-2024 | Farxiga, Lokelma, Evusheld |
| Otsuka America Pharmaceutical, INC. | $442.24 | 2020-2025 | Jynarque |
| Travere Therapeutics, INC. | $287.42 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $279.00 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $235.21 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $214.31 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $201.82 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $198.30 | 2022-2025 | Tarpeyo |
| Akcea Therapeutics, INC. | $158.06 | 2019 | |
| Glaxosmithkline, LLC. | $149.87 | 2022-2024 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $110.76 | 2024-2025 | |
| Akebia Therapeutics INC | $103.05 | 2020-2025 | Vafseo |
| Fresenius USA Marketing, INC. | $71.07 | 2020-2022 | |
| Genzyme Corporation | $65.57 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $62.99 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $57.91 | 2021-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.03 | 2023-2024 | Jardiance |
| Ardelyx, INC. | $38.71 | 2025 | Ibsrela |
| Scpharmaceuticals INC. | $33.26 | 2024 | |
| Amicus Therapeutics, INC. | $31.42 | 2022-2023 | Galafold |
| Apellis Pharmaceuticals, INC. | $22.15 | 2025 | |
| Abbott Laboratories | $20.65 | 2023 | Freestyle Libre 3 |
| Ani Pharmaceuticals, INC. | $19.80 | 2024 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $19.39 | 2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $17.21 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.46 | 2020 | |
| Daiichi Sankyo INC. | $14.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neysha Sanchez Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.